NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RYTM

*Your capital is at risk

$84.71

+0.360 (+0.427%)

At Close: Jun 03, 2026

Rhythm Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 34.39. In total, the insiders bought 890.31K and sold 98.16K RYTM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	34.39
● Buy	890.31K shares
● Sell	98.16K shares
67% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Feb 11, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 34.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	10 413 Value: $882.1K
Feb 01, 2026 Sell	Common Stock F-InKind	Smith Hunter C Chief Financial Officer	C-Suite Officer	10 750 Value: $1.17M
Feb 01, 2026 Buy	Common Stock M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	26 000 Value: $2.20M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	5 500 Value: $465.9K
Feb 01, 2026 Buy	Common Stock M-Exempt	Mazabraud Yann EVP, Head Of International	Officer	5 500 Value: $465.9K
Feb 01, 2026 Sell	Common Stock F-InKind	Meeker David P President And CEO	CEO / President	31 522 Value: $3.44M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Meeker David P President And CEO	CEO / President	33 338 Value: $2.82M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Meeker David P President And CEO	CEO / President	21 250 Value: $1.80M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Meeker David P President And CEO	CEO / President	14 125 Value: $1.20M
Feb 01, 2026 Buy	Common Stock M-Exempt	Lee Jennifer Kayden EVP, Head Of North America	Officer	22 612 Value: $1.92M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Lee Jennifer Kayden EVP, Head Of North America	Officer	9 163 Value: $776.2K
Feb 01, 2026 Sell	Common Stock F-InKind	Lee Jennifer Kayden EVP, Head Of North America	Officer	9 237 Value: $1.01M
Feb 01, 2026 Sell	Common Stock F-InKind	Shulman Joseph Chief Technical Officer	Officer	6 507 Value: $709.2K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Shulman Joseph Chief Technical Officer	Officer	6 250 Value: $529.4K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Shulman Joseph Chief Technical Officer	Officer	4 125 Value: $349.4K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Shulman Joseph Chief Technical Officer	Officer	3 937 Value: $333.5K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Shulman Joseph Chief Technical Officer	Officer	2 656 Value: $225.0K
Feb 01, 2026 Buy	Common Stock M-Exempt	Meeker David P President And CEO	CEO / President	68 713 Value: $5.82M
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Lee Jennifer Kayden EVP, Head Of North America	Officer	5 500 Value: $465.9K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Lee Jennifer Kayden EVP, Head Of North America	Officer	4 512 Value: $382.2K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Lee Jennifer Kayden EVP, Head Of North America	Officer	3 437 Value: $291.1K
Feb 01, 2026 Sell	Common Stock F-InKind	German Christopher Paul Corporate Controller & Cao	Officer	1 138 Value: $124.0K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Garfield Alastair Chief Scientific Officer	Officer	6 663 Value: $564.4K
Feb 01, 2026 Buy	Common Stock M-Exempt	Garfield Alastair Chief Scientific Officer	Officer	6 663 Value: $564.4K
Feb 01, 2026 Buy	Restricted Stock Units M-Exempt	Cramer Pamela J. Chief Human Resources Officer	Officer	5 000 Value: $423.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström s...

Read Full Profile Here